Posted on

Huma, which uses AI and biomarkers to monitor patients and for medical research, raises $130M

While much of the world eagerly watches to see if the vaccination rollout helps curb and eventually stamp out Covid-19, one of the companies that has been helping to manage the spread of the virus is announcing a big round of funding on the heels for strong demand for its technology.
Huma, which combines data from biomarkers with predictive algorithms both to help monitor patients, and uses the same technology to help researchers and pharmaceutical companies run clinical trials, has closed an equity round of $130 million, a Series C that the company can extend to $200 million by way of a $70 …

Read More

Posted on

Watch a monkey equipped with Elon Musk’s Neuralink device play Pong with its brain

[embedded content]
Elon Musk’s Neuralink, one of his many companies and the only one currently focused on mind control (that we’re aware of), has released a new blog post and video detailing some of its recent updates — including using its hardware to make it possible for a monkey to play pong with only its brain.
In the video above, Neuralink demonstrates how it used its sensor hardware and brain implant to record a baseline of activity from this macaque (named ‘Pager’) as it played a game on-screen where it had to move a token to different squares using …

Read More

Posted on

Foresite Capital raises $969 million fund to invest in healthcare startups across all stages of growth

Health and life science specialist investment firm Foresite Capital has raised a new fund, its fifth to date, totally $969 million in commitments from LPs. This is the firm’s largest fund to date, and was oversubscribed relative to its original target according to fund CEO and founder Dr. Jim Tananbaum, who told me that while the fundraising process started out slow in the early months of the pandemic, it gained steam quickly starting around last fall and ultimately exceeded expectations.
This latest fund actually makes up two separate investment vehicles, Foresite Capital Fund V, and Foresite Capital Opportunity Fund V, …

Read More

Revolutionary Stem Cell Technology for Unmet Medical Needs | Min Hu

Revolutionary Stem Cell Technology
for Unmet Medical Needs

Min Hu, MD, PhD
Founder & CEO, APstem Therapeutics


Dr. Hu is the founder of APstem Therapeutics and has been CEO and President since its inception.

She has more than 20 years of experience in the fields of stem cell biology, gene therapy and regenerative medicine.

From a scientist at Stanford University to a leader of a biotech company, Dr. Hu has accumulated solid background knowledge and first-hand experience of clinical cell therapies as well as business operation.


An unprecedented era of stem cell therapy has arrived.

With APstem Therapeutics’ breakthrough discovery of Adult Pluripotent Stem Cells (APSCs™), we are on a mission to eradicate difficult-to-heal diseases and conquer the challenges of aging.

Our lifetime endeavor remains to fight human diseases with no effective cure.

This is especially true when patients face life-threatening medical conditions and chronic diseases. Inspired, our mission has focused on establishing a new paradigm in regenerative medicine.

After over a decade of research at Stanford University — we did just that, with a radical breakthrough in stem cell technology - Adult Pluripotent Stem Cells (APSCs™).

We obtained the worldwide exclusive IP license from Stanford University and established a dedicated facility to further our proprietary research and development.

Posted on

Pfizer-BioNTech’s COVID-19 vaccine just got a lot easier to transport and distribute

The COVID-19 vaccine developed by Pfizer and BioNTech now has less stringent and extreme transportation requirements than it debuted with. Originally, the mRNA-based vaccine had to be maintained at ultra-low temperatures throughout the transportation chain in order to remain viable – between -76°F and -112°F. New stability data collected by Pfizer and BioNTech, which has been submitted to the U.S. Food and Drug Administration (FDA) for review, allow it to be stored at temps between 5°F and -13°F – ranges available in standard medical freezers found in most clinics and care facilities.
The vaccine should remain stable for …

Read More

Posted on

Use today’s tech solutions to meet the climate crisis and do it profitably

Bertrand Piccard
Contributor

Bertrand Piccard initiated the Solar Impulse Foundation after his history-making flight around the world in a solar-powered plane. Fueled only by the rays of the sun, his flight proved that existing methods and technologies can provide clean energy and solutions that protect the environment in a profitable way.

Five years ago I landed the Solar Impulse 2 in Abu Dhabi after flying around the globe powered solely by solar energy, a first in aviation history.
It was also a milestone in energy and technology history. Solar Impulse was an experimental plane, weighing as little as a family car …

Read More

Posted on

Immunai raises $60M as it expands from improving immune therapies to discovering new ones, too

Just three years after its founding, biotech startup Immunai has raised $60 million in Series A funding, bringing its total raised to over $80 million. Despite its youth, Immunai has already established the largest database in the world for single cell immunity characteristics, and it has already used its machine learning-powered immunity analysts platform to enhance the performance of existing immunotherapies, but aided by this new funding, it’s now ready to expand into the development of entirely new therapies based on the strength and breadth of its data and ML.
Immunai’s approach to developing new insights around the human immune …

Read More

Posted on

Moderna says it’s making variant-specific COVID-19 vaccines, but its existing vaccine should still work

Moderna has detailed some of the steps it’s taking to ensure that its vaccine remains effective in the face of emerging strains of the SARS-CoV-2 virus that leads to COVID-19. These include testing how adding a second booster, for a total of three shots, works with its existing COVID-19 vaccine, and also developing a strain-specific variant designed to target spike proteins on the new variants of the virus that were first identified in the UK and in South Africa.
The company is pursuing these measures “out of an abundance of caution,” the biotech firm said in a press release, …

Read More

Posted on

Endeavor BioMedicines raises $62 million to combat pulmonary disease

A new startup has officially emerged for stealth with the raise of its $62 million Series A funding round. Endeavor BioMedicines is led by co-founder and CEO John Hood, who previously led Impact Biomedicines, and its new funding comes from Omega Funds and Longitude Capital, as well as the company’s own management team. Endeavor is also co-founded by Miguel de los Rios, who serves as its Chief Science Officer and who was previously CEO of Rift Biotherapeutics.
Endeavor’s goal is to develop treatments specifically to address pulmonary disease, and the startup is putting its funding towards two Phase 2 clinical …

Read More

Posted on

Color raises $167 million funding at $1.5 billion valuation to expand ‘last mile’ of U.S. health infrastructure

Healthcare startup Color has raised a sizeable $167 million in Series D funding round, at a valuation of $1.5 billion post-money, the company announced today. This brings the total raised by Color to $278 million, with its latest large round intended to help it build on a record year of growth in 2020 with even more expansion to help put in place key health infrastructure systems across the U.S. – including those related to the “last mile” delivery of COVID-19 vaccines.
This latest investment into Color was led by General Catalyst, and by funds invested by T. Rowe Price, along with participation from Viking …

Read More